A STUDY ON HOMOEOPATHIC MANAGEMENT OF ALLERGIC COLD
Phase 4
- Conditions
- Health Condition 1: J309- Allergic rhinitis, unspecified
- Registration Number
- CTRI/2022/04/041644
- Lead Sponsor
- Dr Anand A Kulkarni
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Subjects of all age groups and both sex.
2 Subjects irrespective of their occupation and socio-economic status will be selected.
3 Subjects diagnosed as cases of allergic rhinitis covering clinical features and h/o paroxysmal attack and showing raised Absolute Eosinophil Count ie more than 440cells/cmm and more than 3 eosinophils in nasal secretion.
4 Subjects who have given consent for the study
Exclusion Criteria
1 Subjects with any other chronic diseases and on active treatment.
2 Subjects with any anatomical or pathological irreversible structural changes.
3 Complications of allergic rhinitis like sinusitis, nasal polypi, serous otitis media, orthodontic problems, bronchial asthma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The progress of the treatment of patient shall be assessed as per the guidelines given in the Organon for each individual class of case. <br/ ><br>Recovered: Disappearance of all the presenting complaints that formed the portrait of the disease and normal level of eosinophil count i.e. less than 440 cells/cmm and no eosinophil seen in nasal secretion along with general well-being of the patient. <br/ ><br>Improved: Partial relief of some of the presenting complaints that formed the portrait of the disease with / without relief of clinical features of allergic rhinitis but relapsing of signs and symptoms, decreased in eosinophil count but not restore to normal i.e. more than 440 cells/cmm and eosinophils seen in nasal secretion general well-being of the patient. <br/ ><br>Not Improved: No relief from symptoms and no changes in Absolute Eosinophil Count in both blood and nasal secretion even after sufficient period of treatment, whatsoever. <br/ ><br>Timepoint: 12 months
- Secondary Outcome Measures
Name Time Method The progress of the treatment of patient shall be assessed as per the guidelines given in the Organon for each individual class of case. <br/ ><br>Recovered: Disappearance of all the presenting complaints that formed the portrait of the disease and normal level of eosinophil count i.e. less than 440 cells/cmm and no eosinophil seen in nasal secretion along with general well-being of the patient. <br/ ><br>Improved: Partial relief of some of the presenting complaints that formed the portrait of the disease with / without relief of clinical features of allergic rhinitis but relapsing of signs and symptoms, decreased in eosinophil count but not restore to normal i.e. more than 440 cells/cmm and eosinophils seen in nasal secretion general well-being of the patient. <br/ ><br>Not Improved: No relief from symptoms and no changes in Absolute Eosinophil Count in both blood and nasal secretion even after sufficient period of treatment, whatsoever. <br/ ><br>Timepoint: 24 months